Piper Jaffray
Piper Jaffray is a client-focused, middle market investment bank and institutional securities firm founded in 1895 and based in Minneapolis, Minnesota.
Its Investment Banking activities include raising capital through equity and debt financings for corporate clients; providing financial advisory services relating to mergers and acquisitions to consumer, financial institutions, health care, technology, alternative energy, business services, and industrial growth sectors; underwriting debt issuances for government and non-profit clients; and providing financial advisory and interest rate risk management services.
The company's equity and fixed income institutional sales and trading activities include equity and fixed income advisory and trade execution services for public and private corporations, public entities, non-profit clients, and institutional investors.
Encorium Group, Inc. (Nasdaq: ENCO) 290.5% HIGHER; the company announced the signing of approximately $8.7 million of new business contracts, including selection by a major pharmaceutical company for participation in a swine flu vaccine program.
VIVUS, Inc. (Nasdaq: VVUS) 59.9% HIGHER; announced positive results from two final, phase 3 pivotal 56-week studies, EQUIP (OB-302) and CONQUER (OB-303), evaluating the safety and efficacy of Qnexa, an investigational drug, in more than 3,750 patients across 93 sites. Click here for the full report.
Candela Corporation (NASDAQ: CLZR) 38.3% HIGHER; Syneron Medical Ltd. (NASDAQ: ELOS) and Candela entered into a definitive agreement to combine the companies in an all stock transaction, creating a global leader in medical aesthetic devices. Under the terms of the merger agreement, Candela shareholders will receive 0.2911 ordinary shares of Syneron for each share of Candela common stock they own. Based upon the closing stock price of ...
ARYx Therapeutics, Inc. (NASDAQ: ARYX) 54.9% LOWER; getting slammed in pre-open trading after announcing that a trial of anticoagulant agent tecarfarin did not achieve the primary endpoint of superiority over leading oral anticoagulant warfarin. Click here for the full report.
Targacept, Inc. (Nasdaq: TRGT) 43.4% HIGHER; announced that AstraZeneca (NYSE: AZN) has informed Targacept that it plans to conduct further development of AZD3480 (TC-1734) for attention deficit/hyperactivity disorder and has agreed to make a $10 million milestone payment to Targacept.
Hana Biosciences (Nasdaq: HNAB) 19.2% HIGHER; continuing higher this morning following yesterday's 50% surge.
Amgen ...
Piper Jaffray initiates coverage on Hana Biosciences (NASDAQ: HNAB) with a Buy rating and a $1 price target.
The firm ...
